La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

NervGen Pharma Crescita futura

Future criteri di controllo 0/6

Al momento non disponiamo di una copertura analitica sufficiente per prevedere la crescita e il fatturato di NervGen Pharma.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	55.0%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	09 Sep 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché NervGen Pharma non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

TSXV:NGEN - Stime future degli analisti e dati finanziari passati (CAD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2024	N/A	N/A	-16	-16	1
6/30/2024	N/A	-23	-12	-12	N/A
3/31/2024	N/A	-20	-10	-10	N/A
12/31/2023	N/A	-22	-11	-11	N/A
9/30/2023	N/A	-20	-13	-13	N/A
6/30/2023	N/A	-19	-17	-17	N/A
3/31/2023	N/A	-20	-18	-18	N/A
12/31/2022	N/A	-21	-18	-18	N/A
9/30/2022	N/A	-19	-16	-16	N/A
6/30/2022	N/A	-19	-13	-13	N/A
3/31/2022	N/A	-15	-11	-11	N/A
12/31/2021	N/A	-13	-8	-8	N/A
9/30/2021	N/A	-13	-7	-7	N/A
6/30/2021	N/A	-12	-7	-6	N/A
3/31/2021	N/A	-12	-6	-6	N/A
12/31/2020	N/A	-11	-6	-6	N/A
9/30/2020	N/A	-10	-6	-6	N/A
6/30/2020	N/A	-10	-7	-7	N/A
3/31/2020	N/A	-9	-7	-7	N/A
12/31/2019	N/A	-10	-8	-8	N/A
9/30/2019	N/A	-8	-7	-7	N/A
6/30/2019	N/A	-6	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-1	-1	-1	N/A
9/30/2018	N/A	-1	0	0	N/A
6/30/2018	N/A	0	0	0	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista NGEN è superiore al tasso di risparmio ( 2.2% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di NGEN cresceranno più velocemente del mercato Canadian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di NGEN cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Dati insufficienti per determinare se si prevede che i ricavi di NGEN cresceranno più rapidamente del mercato Canadian.

Ricavi ad alta crescita: Dati insufficienti per determinare se si prevede che i ricavi di NGEN cresceranno più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di NGEN è previsto essere elevato tra 3 anni

NervGen Pharma Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 8.6% to CA$6.00

Recent updates

Insufficient new directors

NervGen Pharma Corp. Appoints Neil Klompas to Board of Directors

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Insufficient new directors

NervGen Pharma Corp. Approves Board and Audit Committee Elections

New minor risk - Market cap size

New major risk - Negative shareholders equity

CEO, President & Director recently bought CA$338k worth of stock

NervGen Pharma Corp., Annual General Meeting, Jun 04, 2024

New minor risk - Market cap size

Independent Director exercised options to buy CA$272k worth of stock.

Co-Founder & Independent Director exercised options to buy CA$347k worth of stock.

New minor risk - Share price stability

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

NervGen Pharma Corp. Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury

Nervgen Pharma Appoints John Ruffolo to Board of Directors

NervGen Pharma Corp. Announces First Subject Dosed in Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Price target increased by 8.6% to CA$6.00

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new and inexperienced directors

Nervgen Pharma Corp. Receives FDA Authorization to Expand Enrollment of Males and Premenopausal Females in Phase 1 Clinical Trial of NervGen's NVG-291

NervGen Pharma Corp. Receives Up to $1.5 Million US Department of Defense Funding to Evaluate NervGen's NVG-291-R for Peripheral Nerve Injury

NervGen Pharma Corp. Announces Executive Changes

NervGen Pharma Corp., Annual General Meeting, Sep 28, 2022

NervGen Pharma Corp. announced that it has received $15.225 million in funding from PFP Biosciences Holdings

NervGen Pharma Corp. Appoints Adam Rogers to its Board of Directors

NervGen Pharma Corp. announced that it expects to receive $15.225 million in funding

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Nervgen Pharma Corp. Receives Approval from the Safety Review Committee to Advance to the Third and Highest Dose Cohort in the Multiple Ascending Dose Portion of Phase 1 Clinical Trial of the Company's Proprietary Lead Compound, NVG-291

President exercised options to buy CA$112k worth of stock.

Independent Director exercised options to buy CA$224k worth of stock.

Less than half of directors are independent

NervGen Pharma Corp. Announces Executive Changes

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

High number of new directors

NervGen Pharma Corp. announced that it has received CAD 2.321075 million in funding

NervGen Pharma Corp. announced that it has received CAD 2.343036 million in funding

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 5.0375 million.

NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

NervGen Pharma Corp. Provides Regulatory Update on Development Program for NVG-291

Nervgen Pharma Adds Alzheimer's Disease Patient Cohort to Its Phase 1 Clinical Trial Program

New 90-day high: CA$2.41

New 90-day high: CA$1.90

New 90-day high: CA$1.85

NervGen Pharma Corp. Appoints Dr. Randall Kaye to the Company's Board of Directors

NervGen Pharma Corp. Provides an Update on NVG-291

New 90-day low: CA$1.43

New 90-day low - CA$1.52

NervGen Pharma Corp. has completed a Composite Units Offering in the amount of CAD 6.45 million.

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita